Clinical Trial Update: Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of Quarfloxin (CX-3543) in patients with low to intermediate grade neuroendocrine tumors completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor

Drugs mentioned

• Quarfloxin (CX-3543)

Snippet

Sponsor: Cylene Pharmaceuticals | Conditions: Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Status: COMPLETED